Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Endocyte nets $81mm through public offering

Executive Summary

Endocyte Inc. netted $81mm through a public offering of 20.5mm common shares (including the overallotment) at $4.20. The company is developing targeted cancer therapies, and will use the proceeds to advance its pipeline of radiopharmaceuticals for metastatic castration-resistant prostate cancer and immunotherapies for osteosarcoma and other tumors.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
  • Pharmaceuticals
    • Drug Delivery
    • Radiopharmaceuticals, Contrast Agents
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register